

Rev05
 Update: Aug,11,2025

DATASHEET


VEGF R3/FLT4 hFc Chimera, Human

Cat. No.: Z03968


Product Introduction

Species	Human
Protein Construction	<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="background-color: #0056b3; color: white; padding: 5px; text-align: center;"> VEGF R3/FLT4 (Tyr25-Ile776) Accession # P35916-1 </div> <div style="background-color: #76b82a; color: white; padding: 5px; text-align: center;"> hFc </div> </div> <div style="display: flex; justify-content: space-around; margin-top: 5px;"> N-term C-term </div>
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per µg by the LAL method.
Biological Activity	Immobilized VEGF-C, His Tag at 1 µg/ml (100µl/Well) on the plate can bind VEGF R3/FLT4 hFc Chimera, Human (Cat.No.: Z03968)
Expression System	HEK293
Theoretical Molecular Weight	111.3 kDa
Apparent Molecular Weight	Due to glycosylation, the protein migrates to 135-155 kDa based on Bis-Tris PAGE result.
Formulation	Lyophilized from a 0.22 µm filtered solution in 50mM Tris, 150mM NaCl, 100mM Glycine (pH 7.5).
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O more than 100 µg/ml.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.


Examples




Immobilized Human VEGF-C, His Tag at 1 $\mu\text{g/ml}$ (100 $\mu\text{l/well}$) on the plate. Dose response curve for VEGF R3/FLT4 hFc Chimera, Human with the EC50 of 8.9 ng/ml determined by ELISA.



Immobilized VEGF R3/FLT4 hFc Chimera, Human, hFc Tag at 2 mg/ml (100 $\mu\text{l/well}$) on the plate. Dose response curve for Human VEGF-D, His Tag with the EC50 of 0.44 $\mu\text{g/ml}$ determined by ELISA.



The purity of VEGF R3/FLT4 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.



VEGF R3/FLT4 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

Background

Target Background : Vascular endothelial growth factor receptor 3 (VEGFR3) is one kind of tyrosine-protein kinase. VEGFR3 acts as a cell-surface receptor for VEGFC and VEGFD. It is a key regulator of lymphatic system development and establishment. VEGFR3 plays important roles in angiogenesis. It is also up-regulated in the endothelium of blood vessels in breast cancer and various other tumors.

Synonyms : VEGFR-3; FLT-4; LMPH1A; PCLFLT41; VEGFR3; FLT-41; PCL

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China